,address1,address2,city,zip,country,phone,website,industry,industryDisp,sector,sectorDisp,longBusinessSummary,fullTimeEmployees,companyOfficers,compensationAsOfEpochDate,maxAge,priceHint,previousClose,open,dayLow,dayHigh,regularMarketPreviousClose,regularMarketOpen,regularMarketDayLow,regularMarketDayHigh,payoutRatio,beta,forwardPE,volume,regularMarketVolume,averageVolume,averageVolume10days,averageDailyVolume10Day,bid,ask,bidSize,askSize,marketCap,fiftyTwoWeekLow,fiftyTwoWeekHigh,priceToSalesTrailing12Months,fiftyDayAverage,twoHundredDayAverage,trailingAnnualDividendRate,trailingAnnualDividendYield,currency,enterpriseValue,profitMargins,floatShares,sharesOutstanding,heldPercentInsiders,heldPercentInstitutions,impliedSharesOutstanding,bookValue,priceToBook,lastFiscalYearEnd,nextFiscalYearEnd,mostRecentQuarter,netIncomeToCommon,trailingEps,forwardEps,enterpriseToRevenue,enterpriseToEbitda,52WeekChange,SandP52WeekChange,exchange,quoteType,symbol,underlyingSymbol,shortName,longName,firstTradeDateEpochUtc,timeZoneFullName,timeZoneShortName,uuid,messageBoardId,gmtOffSetMilliseconds,currentPrice,targetHighPrice,targetLowPrice,targetMeanPrice,targetMedianPrice,recommendationMean,recommendationKey,numberOfAnalystOpinions,totalCash,totalCashPerShare,ebitda,totalDebt,quickRatio,currentRatio,totalRevenue,debtToEquity,revenuePerShare,returnOnAssets,returnOnEquity,grossProfits,freeCashflow,operatingCashflow,revenueGrowth,grossMargins,ebitdaMargins,operatingMargins,financialCurrency,trailingPegRatio
0,Surrey Research Park,10 Nugent Road,Guildford,GU2 7AF,United Kingdom,44 14 8334 3434,https://angleplc.com,Diagnostics & Research,Diagnostics & Research,Healthcare,Healthcare,"ANGLE plc, a medical diagnostic company, engages in developing cancer diagnostics products in Europe, North America, and the United Kingdom. The company develops and commercializes Parsortix cell separation system, which captures and harvests circulating tumor cells in metastatic breast cancer patient blood; and HyCEAD. ANGLE plc has a partnership agreement with Bio View Ltd to develop a liquid biopsy circulating tumor cell HER2 assay for breast cancer. The company was founded in 1994 and is based in Guildford, the United Kingdom.",173,"{'maxAge': 1, 'name': 'Mr. Andrew David William Newland', 'age': 60, 'title': 'Founder, CEO & Exec. Director', 'yearBorn': 1962, 'fiscalYear': 2022, 'totalPay': 264000, 'exercisedValue': 0, 'unexercisedValue': 0}",1672444800,86400,2,16.5,16.3,15.31,16.44,16.5,16.3,15.31,16.44,0.0,0.468468,-2.3550725,535494,535494,1136814,1481293,1481293,15.5,17.0,0,0,42344412,10.65,72.0,23.291756,13.5632,22.801426,0.0,0.0,GBp,24737934,0.0,190412006,260580992,0.10821,0.32424998,260580992,0.123,132.11382,1672444800,1703980800,1688083200,-22278000,-0.09,-6.9,13.607,-1.036,-0.77272725,0.14113986,LSE,EQUITY,AGL.L,AGL.L,ANGLE PLC ORD 10P,ANGLE plc,1079510400,Europe/London,BST,200e5a32-2b7d-30c6-9a5b-18950acf779d,finmb_9804727,3600000,16.25,120.0,75.0,97.5,97.5,1.5,strong_buy,2,22162000,0.085,-23889000,4574000,6.933,7.506,1818000,14.263,0.007,-0.38074002,-0.69681,-163000,-11260750,-14973000,1.854,0.17547001,0.0,-13.73267,GBP,
1,Surrey Research Park,10 Nugent Road,Guildford,GU2 7AF,United Kingdom,44 14 8334 3434,https://angleplc.com,Diagnostics & Research,Diagnostics & Research,Healthcare,Healthcare,"ANGLE plc, a medical diagnostic company, engages in developing cancer diagnostics products in Europe, North America, and the United Kingdom. The company develops and commercializes Parsortix cell separation system, which captures and harvests circulating tumor cells in metastatic breast cancer patient blood; and HyCEAD. ANGLE plc has a partnership agreement with Bio View Ltd to develop a liquid biopsy circulating tumor cell HER2 assay for breast cancer. The company was founded in 1994 and is based in Guildford, the United Kingdom.",173,"{'maxAge': 1, 'name': 'Mr. Ian Francis Griffiths', 'age': 57, 'title': 'CFO, Fin. Director, Company Sec. & Exec. Director', 'yearBorn': 1965, 'fiscalYear': 2022, 'totalPay': 164000, 'exercisedValue': 0, 'unexercisedValue': 19027}",1672444800,86400,2,16.5,16.3,15.31,16.44,16.5,16.3,15.31,16.44,0.0,0.468468,-2.3550725,535494,535494,1136814,1481293,1481293,15.5,17.0,0,0,42344412,10.65,72.0,23.291756,13.5632,22.801426,0.0,0.0,GBp,24737934,0.0,190412006,260580992,0.10821,0.32424998,260580992,0.123,132.11382,1672444800,1703980800,1688083200,-22278000,-0.09,-6.9,13.607,-1.036,-0.77272725,0.14113986,LSE,EQUITY,AGL.L,AGL.L,ANGLE PLC ORD 10P,ANGLE plc,1079510400,Europe/London,BST,200e5a32-2b7d-30c6-9a5b-18950acf779d,finmb_9804727,3600000,16.25,120.0,75.0,97.5,97.5,1.5,strong_buy,2,22162000,0.085,-23889000,4574000,6.933,7.506,1818000,14.263,0.007,-0.38074002,-0.69681,-163000,-11260750,-14973000,1.854,0.17547001,0.0,-13.73267,GBP,
2,Surrey Research Park,10 Nugent Road,Guildford,GU2 7AF,United Kingdom,44 14 8334 3434,https://angleplc.com,Diagnostics & Research,Diagnostics & Research,Healthcare,Healthcare,"ANGLE plc, a medical diagnostic company, engages in developing cancer diagnostics products in Europe, North America, and the United Kingdom. The company develops and commercializes Parsortix cell separation system, which captures and harvests circulating tumor cells in metastatic breast cancer patient blood; and HyCEAD. ANGLE plc has a partnership agreement with Bio View Ltd to develop a liquid biopsy circulating tumor cell HER2 assay for breast cancer. The company was founded in 1994 and is based in Guildford, the United Kingdom.",173,"{'maxAge': 1, 'name': 'Mr. Martin  Cooke', 'age': 53, 'title': 'Director of Operations & Regulatory Affairs', 'yearBorn': 1969, 'exercisedValue': 0, 'unexercisedValue': 0}",1672444800,86400,2,16.5,16.3,15.31,16.44,16.5,16.3,15.31,16.44,0.0,0.468468,-2.3550725,535494,535494,1136814,1481293,1481293,15.5,17.0,0,0,42344412,10.65,72.0,23.291756,13.5632,22.801426,0.0,0.0,GBp,24737934,0.0,190412006,260580992,0.10821,0.32424998,260580992,0.123,132.11382,1672444800,1703980800,1688083200,-22278000,-0.09,-6.9,13.607,-1.036,-0.77272725,0.14113986,LSE,EQUITY,AGL.L,AGL.L,ANGLE PLC ORD 10P,ANGLE plc,1079510400,Europe/London,BST,200e5a32-2b7d-30c6-9a5b-18950acf779d,finmb_9804727,3600000,16.25,120.0,75.0,97.5,97.5,1.5,strong_buy,2,22162000,0.085,-23889000,4574000,6.933,7.506,1818000,14.263,0.007,-0.38074002,-0.69681,-163000,-11260750,-14973000,1.854,0.17547001,0.0,-13.73267,GBP,
3,Surrey Research Park,10 Nugent Road,Guildford,GU2 7AF,United Kingdom,44 14 8334 3434,https://angleplc.com,Diagnostics & Research,Diagnostics & Research,Healthcare,Healthcare,"ANGLE plc, a medical diagnostic company, engages in developing cancer diagnostics products in Europe, North America, and the United Kingdom. The company develops and commercializes Parsortix cell separation system, which captures and harvests circulating tumor cells in metastatic breast cancer patient blood; and HyCEAD. ANGLE plc has a partnership agreement with Bio View Ltd to develop a liquid biopsy circulating tumor cell HER2 assay for breast cancer. The company was founded in 1994 and is based in Guildford, the United Kingdom.",173,"{'maxAge': 1, 'name': 'Dr. Karen  Miller Ph.D.', 'title': 'Chief Scientific Officer', 'exercisedValue': 0, 'unexercisedValue': 0}",1672444800,86400,2,16.5,16.3,15.31,16.44,16.5,16.3,15.31,16.44,0.0,0.468468,-2.3550725,535494,535494,1136814,1481293,1481293,15.5,17.0,0,0,42344412,10.65,72.0,23.291756,13.5632,22.801426,0.0,0.0,GBp,24737934,0.0,190412006,260580992,0.10821,0.32424998,260580992,0.123,132.11382,1672444800,1703980800,1688083200,-22278000,-0.09,-6.9,13.607,-1.036,-0.77272725,0.14113986,LSE,EQUITY,AGL.L,AGL.L,ANGLE PLC ORD 10P,ANGLE plc,1079510400,Europe/London,BST,200e5a32-2b7d-30c6-9a5b-18950acf779d,finmb_9804727,3600000,16.25,120.0,75.0,97.5,97.5,1.5,strong_buy,2,22162000,0.085,-23889000,4574000,6.933,7.506,1818000,14.263,0.007,-0.38074002,-0.69681,-163000,-11260750,-14973000,1.854,0.17547001,0.0,-13.73267,GBP,
4,Surrey Research Park,10 Nugent Road,Guildford,GU2 7AF,United Kingdom,44 14 8334 3434,https://angleplc.com,Diagnostics & Research,Diagnostics & Research,Healthcare,Healthcare,"ANGLE plc, a medical diagnostic company, engages in developing cancer diagnostics products in Europe, North America, and the United Kingdom. The company develops and commercializes Parsortix cell separation system, which captures and harvests circulating tumor cells in metastatic breast cancer patient blood; and HyCEAD. ANGLE plc has a partnership agreement with Bio View Ltd to develop a liquid biopsy circulating tumor cell HER2 assay for breast cancer. The company was founded in 1994 and is based in Guildford, the United Kingdom.",173,"{'maxAge': 1, 'name': 'Mr. Andrew John Holder', 'age': 54, 'title': 'Head of Investor Relations', 'yearBorn': 1968, 'exercisedValue': 0, 'unexercisedValue': 0}",1672444800,86400,2,16.5,16.3,15.31,16.44,16.5,16.3,15.31,16.44,0.0,0.468468,-2.3550725,535494,535494,1136814,1481293,1481293,15.5,17.0,0,0,42344412,10.65,72.0,23.291756,13.5632,22.801426,0.0,0.0,GBp,24737934,0.0,190412006,260580992,0.10821,0.32424998,260580992,0.123,132.11382,1672444800,1703980800,1688083200,-22278000,-0.09,-6.9,13.607,-1.036,-0.77272725,0.14113986,LSE,EQUITY,AGL.L,AGL.L,ANGLE PLC ORD 10P,ANGLE plc,1079510400,Europe/London,BST,200e5a32-2b7d-30c6-9a5b-18950acf779d,finmb_9804727,3600000,16.25,120.0,75.0,97.5,97.5,1.5,strong_buy,2,22162000,0.085,-23889000,4574000,6.933,7.506,1818000,14.263,0.007,-0.38074002,-0.69681,-163000,-11260750,-14973000,1.854,0.17547001,0.0,-13.73267,GBP,
5,Surrey Research Park,10 Nugent Road,Guildford,GU2 7AF,United Kingdom,44 14 8334 3434,https://angleplc.com,Diagnostics & Research,Diagnostics & Research,Healthcare,Healthcare,"ANGLE plc, a medical diagnostic company, engages in developing cancer diagnostics products in Europe, North America, and the United Kingdom. The company develops and commercializes Parsortix cell separation system, which captures and harvests circulating tumor cells in metastatic breast cancer patient blood; and HyCEAD. ANGLE plc has a partnership agreement with Bio View Ltd to develop a liquid biopsy circulating tumor cell HER2 assay for breast cancer. The company was founded in 1994 and is based in Guildford, the United Kingdom.",173,"{'maxAge': 1, 'name': 'Mr. Brett  Swansiger', 'title': 'Chief Commercial Officer', 'exercisedValue': 0, 'unexercisedValue': 0}",1672444800,86400,2,16.5,16.3,15.31,16.44,16.5,16.3,15.31,16.44,0.0,0.468468,-2.3550725,535494,535494,1136814,1481293,1481293,15.5,17.0,0,0,42344412,10.65,72.0,23.291756,13.5632,22.801426,0.0,0.0,GBp,24737934,0.0,190412006,260580992,0.10821,0.32424998,260580992,0.123,132.11382,1672444800,1703980800,1688083200,-22278000,-0.09,-6.9,13.607,-1.036,-0.77272725,0.14113986,LSE,EQUITY,AGL.L,AGL.L,ANGLE PLC ORD 10P,ANGLE plc,1079510400,Europe/London,BST,200e5a32-2b7d-30c6-9a5b-18950acf779d,finmb_9804727,3600000,16.25,120.0,75.0,97.5,97.5,1.5,strong_buy,2,22162000,0.085,-23889000,4574000,6.933,7.506,1818000,14.263,0.007,-0.38074002,-0.69681,-163000,-11260750,-14973000,1.854,0.17547001,0.0,-13.73267,GBP,
6,Surrey Research Park,10 Nugent Road,Guildford,GU2 7AF,United Kingdom,44 14 8334 3434,https://angleplc.com,Diagnostics & Research,Diagnostics & Research,Healthcare,Healthcare,"ANGLE plc, a medical diagnostic company, engages in developing cancer diagnostics products in Europe, North America, and the United Kingdom. The company develops and commercializes Parsortix cell separation system, which captures and harvests circulating tumor cells in metastatic breast cancer patient blood; and HyCEAD. ANGLE plc has a partnership agreement with Bio View Ltd to develop a liquid biopsy circulating tumor cell HER2 assay for breast cancer. The company was founded in 1994 and is based in Guildford, the United Kingdom.",173,"{'maxAge': 1, 'name': 'Mr. Nick  Claxton', 'title': 'Sr. VP of Commercial Operations', 'exercisedValue': 0, 'unexercisedValue': 0}",1672444800,86400,2,16.5,16.3,15.31,16.44,16.5,16.3,15.31,16.44,0.0,0.468468,-2.3550725,535494,535494,1136814,1481293,1481293,15.5,17.0,0,0,42344412,10.65,72.0,23.291756,13.5632,22.801426,0.0,0.0,GBp,24737934,0.0,190412006,260580992,0.10821,0.32424998,260580992,0.123,132.11382,1672444800,1703980800,1688083200,-22278000,-0.09,-6.9,13.607,-1.036,-0.77272725,0.14113986,LSE,EQUITY,AGL.L,AGL.L,ANGLE PLC ORD 10P,ANGLE plc,1079510400,Europe/London,BST,200e5a32-2b7d-30c6-9a5b-18950acf779d,finmb_9804727,3600000,16.25,120.0,75.0,97.5,97.5,1.5,strong_buy,2,22162000,0.085,-23889000,4574000,6.933,7.506,1818000,14.263,0.007,-0.38074002,-0.69681,-163000,-11260750,-14973000,1.854,0.17547001,0.0,-13.73267,GBP,
